Format

Send to

Choose Destination
See comment in PubMed Commons below
Nat Chem Biol. 2012 Feb 12;8(3):311-7. doi: 10.1038/nchembio.790.

Halofuginone and other febrifugine derivatives inhibit prolyl-tRNA synthetase.

Author information

1
Department of Developmental Biology, Harvard School of Dental Medicine, Boston, Massachusetts, USA. tkeller@hms.harvard.edu

Abstract

Febrifugine, the bioactive constituent of one of the 50 fundamental herbs of traditional Chinese medicine, has been characterized for its therapeutic activity, though its molecular target has remained unknown. Febrifugine derivatives have been used to treat malaria, cancer, fibrosis and inflammatory disease. We recently demonstrated that halofuginone (HF), a widely studied derivative of febrifugine, inhibits the development of T(H)17-driven autoimmunity in a mouse model of multiple sclerosis by activating the amino acid response (AAR) pathway. Here we show that HF binds glutamyl-prolyl-tRNA synthetase (EPRS), inhibiting prolyl-tRNA synthetase activity; this inhibition is reversed by the addition of exogenous proline or EPRS. We further show that inhibition of EPRS underlies the broad bioactivities of this family of natural product derivatives. This work both explains the molecular mechanism of a promising family of therapeutics and highlights the AAR pathway as an important drug target for promoting inflammatory resolution.

PMID:
22327401
PMCID:
PMC3281520
DOI:
10.1038/nchembio.790
[Indexed for MEDLINE]
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Nature Publishing Group Icon for PubMed Central
    Loading ...
    Support Center